Evidence map›Paper›PMID 29079283›Full record

ArticleClinical lymphoma, myeloma & leukemia2018

Consolidative Radiotherapy After Autologous Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Brendan G Coutu, Christopher T Wilke, Jianling Yuan, Qing Cao, Matthew R Vernon, Chung Lee, Veronika Bachanova, Kathryn E Dusenbery

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Brendan G CoutuDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN.
Christopher T WilkeDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN.
Jianling YuanDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN.
Qing CaoBlood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN.
Matthew R VernonDepartment of Radiation Oncology, Southwestern Vermont Medical Center, Bennington, VT.
Chung LeeDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN.
Veronika BachanovaBlood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN.
Kathryn E DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, MN. Electronic address: dusen001@umn.edu.
University of Minnesota · USSouthwestern Vermont Health Care · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

introductionWe evaluated the role of consolidative radiotherapy (RT) for patients undergoing high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). MATERIALS AND

methodsWe reviewed the medical records of 72 consecutive patients who had undergone ASCT for relapsed or refractory DLBCL at our institution from 2006 to 2014. Pretransplant conditioning consisted of HDC and total body irradiation. Of the 72 patients, 13 received post-transplant consolidative RT at the discretion of the consulted radiation oncologist.

resultsConsolidative RT was associated with significantly improved 2-year locoregional control (LRC) (92% vs. 68%; P = .04). However, no difference was seen in either the 2-year progression-free survival (PFS) (69% vs. 54%; P = .25) or overall survival (OS) (85% vs. 59%; P = .44). Analysis of the subgroup of 19 patients with persistent residual masses ≥ 2 cm on post-transplant imaging demonstrated a significant improvement in LRC (100% vs. 36%; P < .01), PFS (88% vs. 27%; P = .01), and OS (100% vs. 45%; P = .02) with consolidative RT.

conclusionThe use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ≥ 2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting.

Indexed as

AdultAgedFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalTransplantation, AutologousTransplantation ConditioningASCTDLBCLInvolved-field radiotherapyLocoregional controlResidual mass

Identifiers

PMID29079283
PMCPMC6684333
OpenAlexW2755956696

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.